Thematic Report

Alcohol and drugs
This document is part of a series of 20 thematic reports on road safety. The purpose is to give road safety practitioners and the general public an overview of the most important research questions and results on the topic in question. The level of detail is intermediate, with more detailed papers or reports suggested for further reading. Each report has a 1-page summary.

Contract: This document has been prepared in the framework of the EC Service Contract MOVE/C2/SER/2022-55/SI2.888215 with National Technical University of Athens (NTUA), SWOV Institute for Road Safety Research and Kuratorium für Verkehrssicherheit (KFV).

Version 30 January 2024

Author Original and update: Charles Goldenbeld (SWOV)

Internal Review: Katerina Folla (NTUA)

External Review: Uta Meesmann (Vias institute)

Referencing: Reproduction of this document is allowed with due acknowledgement. Please refer to the document as follows:


Disclaimer

Whilst every effort has been made to ensure that the matter presented in this document is relevant, accurate and up to date, the (sub)contractors cannot accept any liability for any error or omission, or reliance on part or all of the content in another context.

Any information and views set out in this document are those of the author(s) and do not necessarily reflect the official opinion of the European Commission. The Commission does not guarantee the accuracy of the data included in this study. Neither the Commission nor any person acting on the Commission’s behalf may be held responsible for the use that may be made of the information contained therein.

© European Commission, 2024.
The EU does not own the copyright in relation to the following elements:
- Cover page photos, © www.shutterstock.com
Contents
Summary ................................................................................................................. 4
1. What is the problem? ................................................................................. 5
   1.1 Definition and measurement .......................................................... 5
   1.2 Extent of problem ........................................................................... 5
   1.3 Effects of impairment ..................................................................... 6
   1.4 What is the prevalence of impaired driving? ............................... 7
2. How dangerous is impaired driving? ...................................................... 8
   2.1 Share of impairment-related crashes .......................................... 8
   2.2 Cognitive effects ............................................................................ 8
   2.3 Crash risk ....................................................................................... 9
   2.4 Features of impairment-related crashes ....................................... 11
3. Why do drivers drive while impaired? ................................................... 12
4. Rules and legislation .............................................................................. 13
5. Counter measures .................................................................................. 13
   5.1 Decreasing alcohol and drugs consumption ................................. 13
   5.2 Regulation and police enforcement ............................................. 14
   5.3 Responsible driving with medicines .......................................... 15
   5.4 Alternative means of transport .................................................... 15
   5.5 Campaigns, rehabilitation, safety culture .................................. 16
   5.6 Vehicle technology ....................................................................... 16
6. Further reading ....................................................................................... 18
7. References ............................................................................................... 18
Summary

Impairment due to alcohol and/or drugs is a major cause of motor vehicle crashes worldwide. Alcohol, illegal drugs and various prescribed drugs (medicines) impair driver's functional capabilities including reaction time, tracking ability, vision, divided attention and vigilance, which leads to increased crash risk.

The crash risk for drivers with a blood alcohol concentration (BAC) of 0.5 g/L is estimated to be 1.4 times higher than that of a sober driver; at 1.0 g/L nearly 5 times higher; and at 1.5 g/L around 20 times higher. For fatal crashes, the risk curve is even steeper. The crash risk associated with drugs depends on the type of drug. The greatest risk increases for illegal drugs - at least 5 times higher - were found for amphetamines, multiple drug use, and combined alcohol-drugs use. For medicines, risk increases were found for barbiturates (used for headaches/insomnia), benzodiazepines (for anxiety/insomnia), anti-depressants, and opioids/opiates (for pain/sleeping problems).

It has been estimated that 1.5 to 2% of kilometres travelled in the EU are driven with an illegal BAC. This equates to millions of drivers under the influence of alcohol. Around 25% of all road deaths in the EU are alcohol-related. On the positive side, alcohol-related fatalities have decreased somewhat faster than the number of other fatalities. The evidence on the development of drug-related traffic fatalities in EU-countries is scarce. Recent roadside surveys among randomly stopped drivers in EU-countries show alcohol prevalence rates between 0.3-2.7% and drug prevalence rates between 6.0 - 11%.

The reasons people engage in impaired driving reflect the opportunities that society provides for this, as well as personal choice or motivation. In regard to the repeat offenders group, medical (psychiatric) problems related to problematic alcohol and drugs use often underly their habitual pattern of impaired driving.

Countermeasures against impaired driving include: Policies to decrease the consumption of alcohol/drugs, to reduce drink/drug use before driving, strict legislation backed by police enforcement, provision of alternative transport means, awareness campaigns, rehabilitation courses, safety culture in companies, alcohol interlocks, and in-vehicle technology that warns/intervenes when impairment leads to critical events. Measures often work better in combination than when implemented individually, e.g. enforcement combined with campaigns, alcohol interlock combined with medical and psychological guidance.
1. What is the problem?

1.1 Definition and measurement

Impaired driving can be defined as a reduction in the performance of critical driving tasks due to the effects of alcohol or other drugs (Baker, 2007). In this report the term ‘drugs’ refers to alcohol, illegal drugs, and medical treatment (medicines\(^1\)). In most countries the presence of alcohol or drugs is initially tested at the roadside by a screening device and/or field sobriety test. Subsequent evidence for court prosecution is determined by measuring blood alcohol concentration (BAC) or the presence of (illegal) drugs in the blood. The BAC is generally reported in terms of grams of alcohol per litre blood (g/L). To assist European countries in collecting Key Performance Indicators (KPIs) on road safety, guidelines have been given in the EC funded Baseline project for obtaining information on the KPI “Driving under the influence (DUI) of alcohol” (Yannis & Folla, 2023).

1.2 Extent of problem

Impairment due to alcohol and/or drugs is a major cause of motor vehicle crashes world-wide (Brubacher et al., 2018; Fell, 2019; Hels et al., 2011; Marillier & Verstraete, 2019). Most information is available for alcohol. It has been estimated that 1.5 to 2% of kilometres travelled in the EU are driven with an illegal BAC, while around 25% of all road deaths in the EU are alcohol-related (EC, 2018). On the positive side, in many EU countries progress in reducing alcohol-related road deaths has been faster than the overall reductions in road deaths (Le Lièvre et al., 2019; Podda & Meinero, 2022). On average, between 2011 and 2021, in the EU-23\(^2\) alcohol-related road fatalities decreased by 37% while other road fatalities decreased by 30% (Podda & Meinero, 2022). Self-reports on drink-driving in Europe confirm the overall positive trend (Goldenbeld et al., 2020a).

In the framework of the SMART project (2020-2022) ETSC has produced thirty European country reports on drink-driving. The estimates of alcohol-related road deaths (2017-2020 data) in these reports range from high estimates for Portugal (37% killed drivers), Slovenia (37% all road deaths), Ireland (36% of road users), France (32% all road deaths), Spain (29% killed drivers), Croatia (27% all road deaths), Norway (25% all road deaths) to lower figures for Czechia (10% all road deaths), Lithuania (17% all road deaths), and Finland (20% all road deaths).

---

\(^1\) Note that medicines also may be necessary to restore the patient’s ability to drive.
\(^2\) Excluding Bulgaria, Ireland, Italy and Malta.
There is less information on how drug-related traffic injuries and fatalities in Europe is developing. Comparing data of drivers killed in road crashes in Norway within the periods 2001-2010 and 2011-2020, Gjerde & Frost (2023) found a decrease in the prevalence of alcohol but no change in prevalence of illegal drugs and medicines. There is certainly concern about the general development of illegal drug consumption in Europe: “An overarching conclusion I draw from this year’s report is that we are now facing a more complex drug situation, characterised by high availability and greater diversity in patterns of drug consumption. We see from our reporting on the new psychoactive substances phenomenon that almost anything that has psycho-active potential is now at risk of appearing on the market, often mislabelled, meaning that those consuming these substances may be unaware of what they are actually using.” (Alexis Goosdeel director EMCDDA, 2022, p. 4).

In conjunction with this thematic report, a separate document has been prepared on the most recent safety performance indicators for drink-driving and drug driving in the EU (European Commission, 2023).

1.3 Effects of impairment

Both alcohol and drugs (legal and illegal) impair several of the driver's functional capabilities, including reaction time, tracking ability, proper speed management, vision, divided attention, and vigilance. This leads to increased crash risk (e.g. Ogden & Moskowitz, 2004; Martin et al., 2013; Marillier & Verstraete, 2019).

The mechanisms through which alcohol and drugs affect the body, the extent to which they impair driving, and the duration of the impairment differ greatly among drugs (Compton, 2017; Blandino et al., 2022). Álvarez (2011) classified medicines into different risk groups according to their influence on driving ability. Other factors, including patterns of use, reasons for use, dose ingested, mode of administration, tolerance, and driver characteristics, also affect the crash risk level (Beirness et al., 2021).

Several studies have compared impairment by alcohol and cannabis. It appears that drivers under the influence of cannabis tend to compensate for increased task demands or risk while driving, whereas drivers under the influence of alcohol do not (Simmons, 2020; Simmons et al., 2021). The ICADTS cannabis factsheet explains these differences in impairment as follows: “Unlike cannabis, alcohol tends to decrease inhibition, inflate self-confidence, and increase risk-taking behaviour, such as speeding and risky driving manoeuvres. While cannabis does impair several important driving-related skills, it is often associated
with slower driving, increased headway, and a reduced willingness to drive. These results suggest cannabis consumers have a heightened awareness of their impairment and engage in potential compensatory mechanisms but results do not preclude cannabis use impairing driving performance.” (ICADTS, 2022; p. 3).

1.4 What is the prevalence of impaired driving?

In 2021-2022 roadside measurements of drinking and driving among randomly stopped drivers in 8 European countries (Belgium, Greece, Ireland, Latvia, Luxembourg, Netherlands, Poland, and Portugal) indicate that in all these countries, more than 97% of drivers drive within the legal limit for blood alcohol concentration (BAC), with the highest percentages being recorded for Poland (99.7%) and Portugal (99.2%) (Yannis & Folla, 2023). During night-time more drivers exceeded the BAC limit in these countries, with most drivers exceeding the BAC limit in weekend nights (Yannis & Folla, 2023). While compliance appears relatively high, it is nevertheless estimated that within the EU this equates to millions of drivers driving billions of kilometres under the influence of alcohol.

Alternatively, roadside surveys among drug use of randomly stopped drivers in European countries tend to show higher prevalence rates (Netherlands: 6% (Goldenbeld et al., 2021); Spain: 8.2% (Alcañiz et., 2021); Switzerland: 10.5% all drugs and 4.9% illicit drugs (Joye et al., 2022).

In 2018-2019, the prevalence of drugs and alcohol use was studied by self-reports (the ESRA-study), asking about impaired driving in the previous 30 days (Achermann Stürmer et al., 2021; Meesmann et al., 2021). Amongst European drivers, 21% reported they had driven after drinking alcohol, 13% with a BAC over the legal limit, 15% after taking medicines that may affect driving ability, and 5% within 1 hour after taking drugs other than medication. In 2024 these data will be updated by a new ESRA study (ESRA3; see https://www.esranet.eu/about-the-project#esra_3).

---

These surveys were held as part of a pilot study. Therefore, these data might not be representative for the entire countries.
2. How dangerous is impaired driving?

2.1 Share of impairment-related crashes

It has been estimated on the basis of 2007-2009 data that about one quarter of road fatalities in Europe are alcohol-related (European Commission, 2018). There is no recent overall estimate of the number of drug-related casualties in Europe. Based on data in more recent years, in US and Canada slightly over half of injured or killed road users are found to have consumed an impairing substance - alcohol and or legal/illegal drugs (US: Thomas et al., 2022; Canada: Brubacher et al., 2021b). In both these studies the share of drug use among injured or killed drivers was higher than alcohol use. In Europe, a recent Norwegian study provided toxicological findings on substance use (alcohol and/or drugs) among fatally injured road users: about a quarter of fatally injured road users had consumed an impairing substance, with slightly higher share of (illegal or medicinal) drug use (17.4%) than alcohol use (16.0%) among fatally injured road users (Gjerde & Frost 2023).

Most studies on drug-related traffic fatalities have focused on car drivers, but there is also evidence of high levels of illicit drug use among cyclists and pedestrians involved in fatal crashes (McKinley & Tillman, 2021; Pasnin & Gjerde, 2021; Schumann et al., 2021; Tonellato et al., 2021).

2.2 Cognitive effects

Alcohol and drug consumption before driving impairs several of the driver's functional capabilities. In a general review of the effects of alcohol intoxication on cognitive driving tasks, Garrison et al. (2021) conclude that:

- deficits in aspects of visual perception begin at a BAC of 0.3 g/L
- impairments in vigilance start at a BAC of 0.3 g/L
- deficits in divided attention and sustained attention commence at BACs between 0.5 g/L and 0.8 g/L
- problems with dividing attention over several tasks begin at a BAC of 0.8 g/L.

In a review on cognitive impairment by alcohol and drugs, Blandino et al. (2022) conclude that, in contrast to alcohol, for many psychoactive substances there is no good evidence to establish a clear relationship between dose/concentration and degree of cognitive impairment (Blandino et al., 2022).
2.3 Crash risk

For alcohol, the crash risk for drivers with a BAC of 0.5 g/L is estimated to be about 1.4 times higher than that of a sober driver; at 1.0 g/L the risk is nearly 5 times higher, and at 1.5 g/L around 20 times higher (see Figure 1; Blomberg et al., 2005). In general, the risk of a crash increases considerably when a driver is impaired by combined alcohol and drugs. A recent meta-analysis by Høye & Storesund Hesjevoll (2023) confirmed the relationship between BAC level and crash risk as found by Blomberg et al. (2005, 2009).

**Figure 1. Relative increase in risk at increasing blood alcohol content (Blomberg et al., 2005).**

Looking at fatal crash data from both the USA and Great Britain, Allsop (2020) reported that the risk of being involved in a fatal crash is almost doubled at a BAC of 0.3 g/L, 5 times higher at a BAC of 0.5 g/L, and 10 times higher at a BAC of 0.8 g/L. The increase in risk differs for different age and gender groups. For example, for young male drivers (16-19 years), the risk of being involved in a single vehicle fatal crash is already 4 times higher at BACs between 0.2 and 0.5 g/L (Zador et al., 2000).

Table 1 shows the crash risk increase for illegal drugs (Els et al., 2019; Elvik, 2013; Hels et al., 2011; Rogeberg & Elvik, 2016; Rogeberg, 2019). The largest risk increase was found for amphetamines, multiple drug use, and combining alcohol and drugs. The effects of cannabis on driving and crash risk have received a lot of research attention. On a critical note, White & Burns (2021) present evidence that crash risk of cannabis-influenced driving may be overestimated in several studies. Concerning the particular combination of alcohol and cannabis, White
& Burns (2023) argue, that there is no good evidence from epidemiological studies that the co-use of cannabis exacerbates the effect of alcohol on the risk of crashing.

**Table 1. Risk increase for several groups of illegal drugs**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Crash severity (source)</th>
<th>Risk increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphetamines</td>
<td>Fatal (Elvik, 2013)</td>
<td>5.2</td>
</tr>
<tr>
<td></td>
<td>Injuries (Elvik, 2013)</td>
<td>6.2</td>
</tr>
<tr>
<td>Cannabis</td>
<td>Fatal (Elvik, 2013)</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>Injuries (Elvik, 2013)</td>
<td>1.1</td>
</tr>
<tr>
<td></td>
<td>Fatal and injuries (Rogeberg &amp; Elvik, 2016)</td>
<td>1.4</td>
</tr>
<tr>
<td></td>
<td>Fatal and injuries (Els et al., 2019)</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Fatal and injuries (Rogeberg, 2019)</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>Crashes (China-Meyyappan et al., 2023)</td>
<td>1.15</td>
</tr>
<tr>
<td>Cocaine</td>
<td>Fatal (Elvik, 2013)</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>Injuries (Elvik, 2013)</td>
<td>1.7</td>
</tr>
<tr>
<td>Opiates*</td>
<td>Fatal (Elvik, 2013)</td>
<td>1.7</td>
</tr>
<tr>
<td></td>
<td>Injuries (Elvik, 2013)</td>
<td>1.9</td>
</tr>
<tr>
<td>Multiple drugs</td>
<td>Crashes (Hels et al., 2011)</td>
<td>5 - 30</td>
</tr>
<tr>
<td>Combination alcohol &amp; drugs</td>
<td>Crashes (Hels et al., 2011)</td>
<td>20 - 200</td>
</tr>
</tbody>
</table>

*Opiates are a subset of opioids comprising the various products derived from the opium poppy plant, including opium, morphine and heroin (UNODC, 2018).

Table 2 gives an overview of the increase in risk due to different medicines reported in various studies (Chihuri & Li, 2017; Elvik, 2013; LeRoy & Morse, 2008; Olesen et al., 2022). Significant risk increases have been found for driving under the influence of barbiturates (used for treating headaches, insomnia, and seizures), benzodiazepines (used to relieve anxiety and insomnia), antidepressants (used to alleviate depression), and opioids (used to treat pain or sleeping problems).

Some qualifying remarks can be made concerning the overview in Table 2. First, the studies in Table 2 do not always yield consistent findings. For example, findings on the relationship between attention-deficit/hyperactivity disorder (ADHD) medication and crash risk are not in agreement (Chang et al., 2017; Olesen et al., 2022). Also, the studies in Table 2 have grouped specific medicines into general classes of medicines. In a general review and meta-analysis, Rudisill et al. (2018) have looked more specifically at the relationship between specific single medicines and crash risk. Finally, Table 2 is limited to studies on medication use and crash risk, it omits studies that have looked into the relationship between medication and crash responsibility (or culpability) (Brubacher et al., 2021a; Kedia et al., 2023).
### Table 2. Risk increase for various medicine groups

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Crash severity (source)</th>
<th>Risk increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD medication</td>
<td>Motor vehicle crashes (Chang et al., 2017)</td>
<td>0.86 (women) – 0.88 (men)</td>
</tr>
<tr>
<td>ADHD medication</td>
<td>Injury crashes (Olesen et al., 2022)</td>
<td>1.62</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Injury crashes (Elvik, 2013)</td>
<td>1.3</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Injury crashes (Olesen et al., 2022)</td>
<td>1.3</td>
</tr>
<tr>
<td>Antihistamines</td>
<td>Injury crashes (Elvik, 2013)</td>
<td>1.1</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Injury crashes (Olesen et al., 2022)</td>
<td>0.86</td>
</tr>
<tr>
<td>Barbiturates</td>
<td>Crashes motorised (LeRoy &amp; Morse, 2008)</td>
<td>7.5</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>Fatal crashes (Elvik, 2013)</td>
<td>2.3</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>Injury crashes (Elvik, 2013)</td>
<td>1.2</td>
</tr>
<tr>
<td>Benzodiazepines and z-hypnotics</td>
<td>Injury crashes (Olesen et al., 2022)</td>
<td>1.29</td>
</tr>
<tr>
<td>Sedatives incl. z-hypnotics</td>
<td>Motor vehicle crashes (Hansen et al., 2015)</td>
<td>1.9</td>
</tr>
<tr>
<td>Narcotics (strong painkillers)</td>
<td>Crashes motorised (LeRoy &amp; Morse, 2008)</td>
<td>2.2</td>
</tr>
<tr>
<td>Analgesics (mild painkillers)</td>
<td>Injury crashes (Elvik, 2013)</td>
<td>1.0 (none)</td>
</tr>
<tr>
<td>Prescription opioids</td>
<td>Crashes motorised (Chihuri &amp; Li, 2017)</td>
<td>2.3</td>
</tr>
<tr>
<td>Prescription opioids</td>
<td>Motor vehicle collisions (Leon et al., 2022)</td>
<td>Increased*</td>
</tr>
</tbody>
</table>

### 2.4 Features of impairment-related crashes

An in-depth investigation of just over 1,500 fatal passenger car crashes in Norway from 2005 to 2015 revealed a number of driver, road and vehicle features associated with impairment-related crashes (Høye, 2020):

- Night-time and weekends are over-represented in alcohol-impaired and alcohol/drug-impaired crashes.
- Young drivers are under-represented among drug- and drug/alcohol-impaired drivers, but not among alcohol-impaired drivers.
- Old cars and cars without electronic stability control (ESC) are over-represented in alcohol-related crashes, but not in alcohol/drug-related crashes.
- Road curves are over-represented in impairment-related crashes, except in drug-related crashes.
- Alcohol-related crashes are over-represented on roads with high-speed limits and under-represented on roads with low-speed limits.
- The average annual daily traffic (AADT) is lower on roads with alcohol-related crashes than on roads with crashes involving sober drivers.

Based on the Norway case-study, alcohol-related crashes are strongly correlated with being unbelted, unlicensed and male, and with single-vehicle crashes in conditions of low traffic volumes.
3. Why do drivers drive while impaired?

People engage in impaired driving because they want to do so (motivation), have the capability to do so, and have the opportunity to do so (Michie et al., 2011). Opportunity factors such as retail availability of alcohol, alcohol serving and sales practices, and the price of alcohol have a great impact on actual drinking patterns and on subsequent drink-driving (PIRE, 2012).

According to the theory of planned behaviour (TPB), the intention to engage in impaired driving can be explained by attitudes towards the particular behaviour, the subjective norms, and the perceived difficulty of performing the behaviour (Marcil et al., 2001; Parker et al., 1992). Additional variables, including personality characteristics such as sensation-seeking, sense of invulnerability, and impulsiveness, provide a fuller explanation of impaired driving (Chan et al., 2010; Cestac et al., 2011; Moan & Rise, 2011; Vankov & Schroeter, 2021). Other studies have highlighted the unplanned nature of impaired driving and have shown how peer pressure and the social situation (e.g. others around you drinking) can change a person’s original plan not to drink and drive (Sykes et al., 2010; Keatly et al., 2016).

For the repeat alcohol offenders group, medical (psychiatric) problems related to problematic alcohol and illegal drug use often underly a habitual pattern of impaired driving (Streff et al., 2001; Nochajski & Stasiewicz, 2006; Goldenbeld et al., 2016). Looking at drivers who use illegal drugs, an Australian study found that 95% reported problematic drug use, i.e. showing indications of addiction (Hasan et al., 2023). People using illegal drugs before driving consider some of these drugs (e.g. cannabis) as producing less impairment than other drugs or alcohol (Kelly et al., 2004; Watson et al., Goodman et al., 2019).

For drivers driving under the influence of medicines, the personal, social, and legal setting is different and therefore the underlying motivation is also different. Many of the drivers who use (multiple) medicines are not fully aware of the possible risks. Information on medicines and driving does not reach all users, or users do not read or understand the information (SWOV, 2020). Also, health professionals may lack sufficient knowledge of the risk of driving with medication (Artiem et al., 2019; SWOV, 2020). In addition, information on the effects of medicines seems to lead to only temporary behavioural effects (Orriols et al., 2016). Experience with medicines may even lead a patient to overestimate their ability to drive (Sargent-Cox et al., 2011).
4. Rules and legislation

Most EU countries apply a legal blood alcohol limit of 0.5g/L, but Lithuania has a legal limit of 0.4g/L; Poland, Sweden and Norway of 0.2g/L. The Czech Republic, Hungary, Romania, and Slovakia have a zero limit. Calinescu & Adminaite (2018) report that 22 EU countries apply a lower legal limit for novice drivers and 19 EU countries for professional drivers; in both cases 0.0g/L or 0.2g/L.

Legislation against drugged driving in EU countries has applied ‘per se’ laws that establish a fixed substance limit or zero tolerance laws. These laws are often combined with legislation that defines how the impairment should be proven (Atchison, 2017).

The EU Driving Licence Directive 2006/126/EC states that ‘Driving licences shall not be issued to or renewed for applicants or drivers who are dependent on psychotropic substances or who are not dependent on such substances but regularly abuse them, whatever category of licence is requested’ (Article 15). In a European Commission proposal in March 2023 to update licence requirement, the EU proposed to introduce a zero tolerance law for novice drivers, i.e. novice drivers should be subject to a zero-tolerance alcohol limit for a minimum of two years after passing their test. The proposals will be considered by the European Parliament and the Council under the ordinary legislative procedure (EC, 2023).

Seven EU countries (Denmark, Finland, Hungary, Ireland, Lithuania, Spain and Sweden) have national guidelines on how patients should be informed of the impact of a prescribed medicine on their fitness to drive (ETSC, 2021).

5. Counter measures

5.1 Decreasing alcohol and drugs consumption

General health policies that decrease the (excessive) consumption of alcohol contribute effectively to the reduction of impaired driving (PIRE, 2012). For example, policies which set a minimum price and increase taxes for alcohol beverages, and which set strict marketing regulations and limit availability of alcohol beverages for children and young adults have been effective in reducing alcohol-related harm (Burton et al.,

---

2016; Teutsch et al., 2018). Less is known about how health policies may affect drug-impaired driving (Razaghizad et. al, 2021). The EU has formulated a common drug policy strategy for 2021-2025, including targeting high-risk crime groups, counteracting digitally enabled illicit drug markets, evidence-based prevention interventions, and provision of alternatives to coercive sanctions (Official Journal of the European Union, 2021).

5.2 Regulation and police enforcement

The adoption of legal measures and enhanced enforcement, as well as changing public attitudes towards drink-driving, have contributed to a decrease of road deaths attributed to alcohol in a number of EU countries (Modijefsky et al., 2021; Podda & Meinero, 2022). It is recommended that enforcement of drink-driving is intensified by setting annual targets for the number of police roadside alcohol checks (Podda & Meinero, 2022).

As part of a proposal in March 2023 for updated driving licence requirements, the European Commission has proposed that novice drivers should be subject to a zero-tolerance alcohol limit for a minimum of two years after passing their test (EC, 2023). In practice this could mean an enforcement limit of 0.2g/L (Calinescu & Adminaite, 2018). The main arguments for a 0.2g/l enforcement limit (rather than zero) are to take account of the possibility of inaccuracy in breath testing devices at these low levels, and to avoid (falsely) prosecuting drivers who only have some small amount of alcohol in the mouth without having consumed alcohol.

Evidence worldwide (see SWOV, 2021 for an overview) shows that lowering the general legal blood alcohol limit from 0.5/0.6 g/L to 0.2/0.3 g/L as well as lowering the legal limit for novice drivers to 0.0 or 0.2 g/L would have a favourable effect on road safety. However, lowering legal limits has an effect only when combined with highly publicised, visible, and frequent police enforcement, preferably deploying random breath-testing methods (Erke et al., 2009; Fell, 2019). There is no clear evidence that more severe penalties are effective in reducing alcohol offences when rather severe penalties already exist (SWOV, 2021).

In an evidence review on interventions on drug driving (illegal and legal), Razaghizad et al. (2021) conclude that state sanctions, including traffic offence criminalization, license withdrawal, and per se drugged

---

5 The policies to legalize cannabis have been subject to research but the evidence on effects on drug-impaired driving is not conclusive (González-Sala et al., 2023)
driving laws\(^6\), may have little or no effect on drug-related fatalities or injuries. Drug driving is a complex problem with many more general social, medical and psychological aspects that cannot be ignored. Hence, there is no single simple solution.

### 5.3 Responsible driving with medicines

ETSC (2021) has proposed several policy measures which may improve responsible driving with medicines, including (p. 8-9):

- Within national medical-fitness-to-drive guidelines and regulations, stress the role of General Practitioners (GPs) as the primary point of call for identifying those who may be at-risk in terms of their fitness to drive, initiating an assessment of a person’s fitness to drive, and influencing how long and under what circumstances a person continues driving.
- As part of their initial and continuous training, inform and/or remind doctors of their duty to advise their patients on the impact of prescription medicines on driving.
- Apply the DRUID categorisation and labelling of medicines – as described in De Gier et al., 2011 - that affect driving ability and support information campaigns promoting awareness among medical professionals and among the general population.
- Regarding the latter: the European DRUID project showed that physicians and pharmacists play a key role in informing patients about the effects of medication on driving. The DRUID categorisation and medicine labelling as well as integrated patient information into the daily software packages of physicians and pharmacists have proven to be effective in providing information to the patient (Meesmann et al., 2011; Touliou et al., 2011).

### 5.4 Alternative means of transport

Promoting the use of alternative means of transport – e.g. free or subsidised taxi and ride-sharing services, voluntary or paid designated driver programmes, or more accessible public transport – is a possible strategy for reducing impaired driving (Fell et al., 2020). However, the evidence regarding effectiveness in terms of drink-driving, drink-driving offences, or crashes is inconclusive. The lack of transport options in rural areas is often cited as a barrier to preventing drink-driving (Howard et al., 2020).

---

\(^6\) Under ‘per se’ drug driving laws it is an offence to operate a vehicle with a concentration of alcohol or drugs in the body above a specified threshold value. If a per se law sets the threshold value at zero, then it is often called a ‘zero tolerance’ law.
5.5 Campaigns, rehabilitation, safety culture

Road safety campaigns on drink-driving can help to increase awareness, change social norms and inform people how to change behaviour (Delhomme et al., 2009; SWOV, 2017). However, general publicity campaigns as a stand-alone measure without related police enforcement cannot be expected to actually change behaviour and reduce alcohol-related crashes (Fell, 2019). According to a review by Razaghizad et al. (2021) there is only low certainty evidence that targeted drug-driving campaigns can increase deterrent attitudes and knowledge.

Rehabilitation courses provide an alternative treatment for alcohol or (illegal) drug driving offenders, aiming at reducing recidivism (Boets et al., 2008). The courses are educational or psychologically oriented, typically organised in small groups (Slootmans et al., 2017). Rehabilitation programmes are commonly provided by private organisations, following national guidelines, and can be voluntary or compulsory, depending on the country and offence in question (Houwing, 2016; Atchison, 2017). There is evidence that rehabilitation can decrease recidivism (Slootmans et al., 2017). However, not all studies show positive results. According to Razaghizad et al. (2021) for adolescents, young adults, and previous (illegal) drug offenders, there is “…moderate-certainty evidence that motivational interviewing can prevent drugged driving and that driver education programs can increase deterrent attitudes and knowledge regarding drugged driving” (Razaghizad et al., 2021; p. 276).

For professional drivers, employers can play an important role. As part of a safety culture approach, employers must clearly set, communicate, and monitor company policies for impaired driving through education, testing, and employee assistance programmes (Transport Safety Group, 2006). Periodically in-company screening drivers for alcohol/illegal drugs has shown positive results in US transport companies (Camden et al., 2019).

5.6 Vehicle technology

Alcohol interlocks are automatic control systems to prevent driving with excess alcohol by requiring the driver to blow into an in-car breathalyser before starting the ignition. Research has shown that alcohol-interlock programmes (AIPs) reduce the risk of recidivism by 75% during the period when the interlock is operational (Bax et al., 2001; Elder et al., 2011; Nieuwkamp et al., 2017; Modijefsky et al.,

---

7 Motivational interviewing is a counselling approach aimed at helping people to find the motivation to make a positive behavioural change.
2021), they reduce alcohol-related fatalities (McGinty et al., 2016; Teoh et al., 2018) and they have favourable cost-benefits (Goldenbeld et al., 2020b). For some AIPs the effects continued after removal of the alcohol interlock device (Bjerre & Thorsson, 2008; Gustafsson & Forsman, 2016; Voas et al., 2016). These AIPs included medical and psychological guidance that was continued after removal of the interlock. In 2022 (new vehicle types) and 2024 (new vehicles) an alcohol interlock installation facilitation will be mandatory for cars, vans, trucks, and buses (Official Journal of the European Union, 2019).

Advanced driver assistance systems (ADAS) can help to warn or intervene in timely manner when a critical driving situation arises, e.g. due to alcohol or drug impairment. The most promising ADAS for alcohol-impaired drivers are lane departure warning systems and forward collision warning systems (Teutsch et al., 2018).

Driver monitoring systems (DMS) collect observable driving information to make real-time assessments of drivers’ capacity to perform the driving task (Haley et al, 2021). DMS are recommended as a primary safety feature for European vehicles seeking a 5-star EuroNCAP safety rating (EuroNCAP, 2020). According to Haley et al. (2021), these systems can be functionally adapted and expanded to reliably detect driving impaired by alcohol or drugs.
6. Further reading


7. References


